All‐cause mortality · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Alirocumab showed no clear difference in all‐cause mortality compared with ezetimibe and statins (low certainty).
1 finding from 1 review
Myocardial infarction · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Alirocumab showed no clear difference in myocardial infarction compared with ezetimibe and statins (low certainty).
1 finding from 1 review
Stroke · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Alirocumab showed no clear difference in any stroke compared with ezetimibe and statins (low certainty).
1 finding from 1 review
CVD · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
It is very uncertain whether evolocumab changes CVD compared with ezetimibe and statins (very low certainty).
1 finding from 1 review
All‐cause mortality · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
It is very uncertain whether evolocumab changes all‐cause mortality compared with ezetimibe and statins (very low certainty).
1 finding from 1 review
Myocardial infarction · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
It is very uncertain whether evolocumab changes myocardial infarction compared with ezetimibe and statins (very low certainty).
1 finding from 1 review
Stroke · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
1 finding from 1 review
All‐cause mortality · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Alirocumab leads to lower all‐cause mortality compared with placebo (high certainty).
1 finding from 1 review
Myocardial infarction · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Alirocumab leads to lower myocardial infarction compared with placebo (high certainty).
1 finding from 1 review
Stroke · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Alirocumab leads to lower any stroke compared with placebo (high certainty).
1 finding from 1 review
CVD · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Evolocumab leads to lower CVD compared with placebo (high certainty).
1 finding from 1 review
All‐cause mortality · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Evolocumab showed no clear difference in all‐cause mortality compared with placebo (high certainty).
1 finding from 1 review
Myocardial infarction · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Evolocumab leads to lower myocardial infarction compared with placebo (high certainty).
1 finding from 1 review
Stroke · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Evolocumab leads to lower any stroke compared with placebo (high certainty).
1 finding from 1 review
CVD · people at high risk of CVD (history of CVD or high LDL‐C despite treatment)
Alirocumab showed no clear difference in CVD compared with ezetimibe and statins (low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality: up to 3 months' · participants with alcoholic hepatitis at high risk of mortality and morbidity
It is very uncertain whether the intervention changes all‐cause mortality: up to 3 months' (very low certainty).
1 finding from 1 review
Intervention not reported
Health‐related quality of life: up to 3 months ( · participants with alcoholic hepatitis at high risk of mortality and morbidity
The intervention showed no clear difference in health‐related quality of life: up to 3 months ( (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events during treatment · participants with alcoholic hepatitis at high risk of mortality and morbidity
It is very uncertain whether the intervention changes serious adverse events during treatment (very low certainty).
1 finding from 1 review
Intervention not reported
Liver‐related mortality: up to 3 months' · participants with alcoholic hepatitis at high risk of mortality and morbidity
It is very uncertain whether the intervention changes liver‐related mortality: up to 3 months' (very low certainty).
1 finding from 1 review
Intervention not reported
Participants with any complication: up to 3 months following randomisation · participants with alcoholic hepatitis at high risk of mortality and morbidity
It is very uncertain whether the intervention changes participants with any complication: up to 3 months following… (very low certainty).
1 finding from 1 review